Ariad Pharmaceuticals Given New $9.00 Price Target at Leerink Swann (ARIA)
Stock analysts at Leerink Swann cut their target price on shares of Ariad Pharmaceuticals (NASDAQ:ARIA) to $9.00 in a report issued on Thursday, AmericanBankingNews.com reports. Leerink Swann’s target price indicates a potential upside of 54.37% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at Summer Street downgraded shares of Ariad Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note to investors on Thursday. Separately, analysts at Chardan Capital downgraded shares of Ariad Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note to investors on Thursday. Finally, analysts at Oppenheimer cut their price target on shares of Ariad Pharmaceuticals from $24.00 to $7.00 in a research note to investors on Thursday. They now have an “outperform” rating on the stock. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating and six have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $17.86.
Ariad Pharmaceuticals (NASDAQ:ARIA) opened at 5.83 on Thursday. Ariad Pharmaceuticals has a 52 week low of $4.00 and a 52 week high of $25.40. The stock’s 50-day moving average is $19.16 and its 200-day moving average is $18.46. The company’s market cap is $1.079 billion.
Ariad Pharmaceuticals (NASDAQ:ARIA) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.37) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.40) by $0.03. The company had revenue of $13.90 million for the quarter, compared to the consensus estimate of $11.11 million. During the same quarter in the prior year, the company posted ($0.31) earnings per share. The company’s quarterly revenue was up 4302.5% on a year-over-year basis. Analysts expect that Ariad Pharmaceuticals will post $-1.63 EPS for the current fiscal year.
ARIAD Pharmaceuticals, Inc (NASDAQ:ARIA) is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.